Analysis | Metabolite Name | Measured Value | Units | Gender | Glycemic status | Neuropathy |
---|---|---|---|---|---|---|
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 5572 | Peak area normalized | male | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 11587 | Peak area normalized | male | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 15085 | Peak area normalized | female | Diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 15760 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 17101 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 17375 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 18413 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 18641 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 18773 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 19727 | Peak area normalized | male | Normoglycemic | Neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 20541 | Peak area normalized | female | Diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 22120 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 22320 | Peak area normalized | male | Normoglycemic | no neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 24260 | Peak area normalized | male | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 25939 | Peak area normalized | male | Diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 26391 | Peak area normalized | male | Normoglycemic | no neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 27665 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 27701 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 28010 | Peak area normalized | female | Diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 29891 | Peak area normalized | male | Diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 30049 | Peak area normalized | male | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 33342 | Peak area normalized | female | Diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 33911 | Peak area normalized | male | Normoglycemic | Neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 36434 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 37963 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 38498 | Peak area normalized | male | Diabetic | no neuropathy |